Introduction
Methods
Search strategy
Study selection
Data extraction
Study characteristics
Authors and year of publication (reference number) | Study population | Study design | Work ability | Late effects of cancer treatment and work ability (> 2 years after diagnosis) | Job resources and work ability | |||
---|---|---|---|---|---|---|---|---|
Type of cancer, N = (ex-) cancer patients in analysis, (gender), age in years, (% at work, type of employment), setting | Study approach and time points measured | Assessment method | Results in general | Physical complaints | Fatigue | Cognitive complaints | Job resources: social support, leadership style, coaching, autonomy, organizational culture | |
Bains et al. (2012) | Colorectal, primary diagnosis with curative treatment, N = 49 at T2, 44% female, mean age 52.49 (SD 5.42), 39% working at T2, United Kingdom | Longitudinal, T0 = post-surgery/pre-treatment, T1 = 3 months, T2 = 6 months | WAI item 1 is described (the method refers to three items) | Item 1: High work ability at baseline was associated with greater work ability at follow-up (β = 0.67, t = 3.99, p = .0005, f2 = 0.53) | ||||
Bielik et al. (2020) | Ovarian, 13.8% metastatic, N = 123, female, mean age 59.7, 34.1% currently employed, Slovakia | Cross-sectional, mean 3.13 years after diagnosis | Current work ability 1 (worst)–10 (best) work ability covered by different dimensions surveys | Current work ability: Full health: 9.58 Without cancer: 9.07* At diagnosis: 4.20* At time of survey: 6.22 *Significant difference p < .001 | ||||
Carlsen et al. (2013) | Breast, N = 170, recurrence excluded, female, mean age 54.2 (range 42–64), controls N = 391, Denmark | Case–control, 5–8 years after diagnosis | WAI item 1 | Item 1: mean 8.66 (controls 8.99), p < .0001 | Fatigue (often), was associated with reduced work ability in a fully adjusted model (also controlled for health-related factors) (OR 10.7, CI 3.31–34.3) [stronger as among controls, 4.11 (1.97–8.57)] | Less help and support from a supervisor was significantly associated with reduced work ability (OR 2.40; CI 1.04–5.54) among the cancer survivors in the full model (also controlled for health-related factors). The latter was not the case for help and support from colleagues, but when only controlled for age this support showed a significant association (OR 3.47, CI 1.73–6.97) | ||
Cheung et al. (2017) | Breast, primarily diagnosed, N = 151, mean age 49.98 (range 22–66), 43.1% currently working, 9.7% self-employed, Hong Kong | Cross-sectional, 1–16 years after diagnosis Work ability before diagnosis, during treatment and currently reported at time of survey | WAI items, 1, 2, 3, and 6 | Item 1: work ability before diagnosis mean 8.48, SD 1.26, during treatment mean 4.95, SD 2.91, current mean 7.21, SD 1.81 Item 2 physical work ability (N = 54): 7.4% very good, 1.1% good, 64.8% moderate, 13.0% poor Item 2 mental work ability (N = 55): 10.9% very good, 45.5% good, 36.4 moderate, 5.5% poor 1.8 very poor Item 6 35% of the currently working not sure if they could continue to work in the subsequent 2 years Work ability before the diagnosis and work ability during treatment were associated with current work ability (0.63, p = .005 resp. .49, p < .0001) higher current work ability if less effects of health-related problems | Control at work was correlated with current work ability (Spearman’s rho 0.29, p = .038) | |||
Couwenberg et al. (2020) | Rectal, N = 172, 8,7% metastatic, 71% male, median age 57, 100% paid employment, Dutch | Prospective cohort study (survey before treatment, 3, 6, 12, 18, and 24 months after treatment) controls N = 58 | WAI | Significant decrease at 3, and 6 months Significantly lower than controls at 24 months | ||||
Dahl et al. (2020) | Prostate, N = 730, 100% male, mean age 65.5 (SD 5.9), 46% working at time of survey, Norway | Cross-sectional, 3 years (SD 1.4) after treatment | WAI item 1 | Current work ability 7.4 (SD 2.1) | ||||
Dahl et al. (2016) | Prostate, N = 563, mean age 62.6 (SD 5.38) with 66% < 65 years, 93% working at time of survey, Norway | Cross-sectional, merge of national prospective study (questionnaires at baseline, 3, 12 and 24 months) and a cross-sectional single-hospital based survey, performed up to 6 years after radical prostatectomy | WAI items 1 and 2 | Item 1 (N = 563): 8.6 (SD 0.5) Score 10: 30%, 8–9: 46%, 6–7: 15%, 0–5: 9% Item 2 (N = 542) physical work ability 55% very good, 28% pretty good, 13% fairly good, 3% quite bad, 1% very bad Item 2 (N = 539) mental work ability: 56% very good, 28% pretty good, 12% fairly good, 3% quite bad 1% very bad | ||||
Dahl et al. (2019) | Breast, colorectal, leukemia, non-Hodgkin lymphoma, melanoma 63% female, median age 49 years (range 27–65), N = 1189, 75% employed (3% sick leave), Norway | Cross-sectional, median time since first cancer diagnosis was 16 years (range 6–31) | WAI item 1 | Current work ability 8.3 (SD 1.8) among employed | Those with low work ability reported significantly higher mean levels of general health p < 0.001 | Those with low work ability reported significantly higher mean levels of total fatigue p < 0.001 | ||
De Boer et al. (2011) | Esophageal, stomach, colorectal, hepatic, pancreatic or biliary, new patients, 22% female, mean age 56 (SD 8), N = 333, 95 (self-) employed of whom 45 participated, the Netherlands | Cross-sectional, before treatment | WAI items 1 and 2 | Item 1: mean current work ability was 5.4; for the subgroup not on sick leave higher (7.1, SD 2.7), than for the subgroup on sick leave (3.7, SD 2.2), p < .001 Item 2: Physical work ability and mental work ability higher for the group not on sick leave | ||||
De Boer et al. (2008) | Breast, female genitals or genito-urological mostly, primary diagnosis of cancer, N = 195 at T3 (24% already returned to work at 6 months), 60% female, mean age 42.2 (SD 9.3), the Netherlands | Longitudinal (prospective), T1 = 6 months after first day of sick leave, T2 = 12 months after first day of sick leave, T3 = 18 months after first day of sick leave | WAI items 1 and 2 | Item 1: significant rise in scores from T1 to T2 and from T2 to T3 (4.6, SD 3.2, 6.3, SD 2.7, and 6.7, SD 2.7 resp.) Both men and women improved over time (p < .001), but women improved more (p = .002) Patients with cancer of the female genitals and breast cancer patients improved most over time (p = .01) | ||||
Doll et al. (2016) | Uterine, ovarian, cervical, vulvar, and other (only new), and also benign disease, N = 185 at baseline, female, mean age 56.5 (SD 13), N = 174 at T3, United States of America | Longitudinal (prospective), T1 = 1 month after surgery, T2 = 3 months after surgery, T3 = 6 months after surgery | A subset of questions of the WAI, in this study item 1 is used | Item 1: Baseline without surgical complications 8.8 (SD 2.3), with surgical complications 7.7 (SD 3.2) | ||||
Duijts et al. (2017) | Various (48% breast), part 1 of the study: N = 252, 69.8% female, mean age 50.7 (SD 7.4) at T0, all with employment contract) at T2, self-employed, temporary agency workers and workers without an employment contract excluded, The Netherlands | Longitudinal (prospective), T0 = 2 years after diagnosis, T1 = 3 years after diagnosis, T2 = 4 years after diagnosis | WAI item 1 | Item 1: Group N = 151 ‘continuously working’ 5.6 (SD 1.8) Multivariate time lag model: current work ability predictor of work continuation one year later (p = .007), ß = 0.38 (SE 0.14)/ OR 1.46; CI 1.11–1.92) | ||||
Fosså et al. (2015) | Prostate, N = 612 (30% working), mean age 69 (range 47–105, with 30% < 65) Norway | Cross-sectional, median observation time since diagnosis 4.0 years (range, 0–23 years) | Self-reported reduction of work ability (“no”: score of 0–5 vs. “yes”: score of 6–10) | Limitations of work ability: 10–22% | Significantly fewer patients experienced limitations of their work ability after radical prostatectomy (10%) than after high-dose radiotherapy (22%) | |||
Gregorowitsch et al. (2019) | Breast, N = 939 (68% employed at baseline, median age 52), The Netherlands | Prospective cohort study (baseline, 6, 18, and 30 months) Controls N = 3,641 | WAI | Employed: baseline 71% moderate-poor work ability 30 months 24% moderate-poor work ability (lower than controls) | ||||
Gudbergsson et al. (2008a) | Breast, testicular, or prostate, N = 446 (all returned to work), 51% female, age 49.1 (SD 9.3), (also self-employed) and norm group N = 588, Norway | Case–control 2–6 years after primary surgery or chemotherapy | WAI items 1, 2 and 3 | Item 1: Survivors scored lower (mean 8.2, SD 2.0) than norm group (mean 8.6, SD 1.6), p < .001, effect size 0.25 Item 2: Survivors scored more moderate/rather poor/poor physical work ability (21% versus 9%, p < .001, effect size 0.34) and more moderate/rather poor/poor mental work ability (19% versus 9%, p < .001, effect size 0.30) | Survivors experienced more support from colleagues at work (p = .005), but similar control as the norm group No data on possible associations of these factors with work ability reported | |||
Gudbergsson et al. (2008b) | Breast, testicular, or prostate, first cancer diagnosis between 25–57 years of age, N = 513, 51% female, 84% had returned to work, and of this group 83% had no work changes and 17% did have work changes, Norway | Cross-sectional, 2–6 years after primary treatment | WAI items 1, 2, and 3 | Item 1: the subgroup with work changes scored lower (mean 6.9, SD 2.4) than group without work changes (mean 8.5, SD 1.8), p < .001, effect size 0.75 Item 2: The subgroup without work changes scored less low (moderate, rather poor, poor) on physical work ability (16% versus 38%) and mental work ability (14% versus 30%) than the subgroup with work changes (both p < .001, effect sizes 0.51 and 0.61) Mental work ability (and not physical work ability) reduced due to cancer was associated with current work ability in univariate and multivariate analyses (ß −0.139, p = .003) | Symptom scale score was associated with current work ability in univariate analyses (ß = 0.396, p < .001) | Social support from colleagues was associated with current work ability in univariate analyses (ß = 0.241, p < .001) No data on possible association of control with work ability reported | ||
Gudbergsson et al. (2011) | Breast, testicular, or prostate, N = 446, 52% female, mean age 52.9 (SD 6.5), and control group N = 588, Norway | Case control, 2–6 years after primary treatment | WAI items 1, 2 and 3 | Item 1: males had a higher work ability (8.4, SD 1.8) than females (8.0, SD 2.1), p = .04, effect size = 0.20) No gender differences in control group (8.6, SD 1.6) Item 2: No difference in physical work ability or mental work ability between male and female survivors Difference between male survivors and male controls on physical work ability (effect size 0.37, p < .001) and mental work ability (effect size 0.27, p = .004) Difference between female survivors and female controls on mental work ability (effect size 0.30, p < .001). No gender difference between female survivors and female controls on physical work ability | Somatic symptoms were associated with overall current work ability in univariate analyses and multivariate analyses (ß =−0.078, p = .012) | Support from colleagues and supervisors was assessed and combined with communication No separate data of an association of only social support with overall current work ability | ||
Hartung et al. (2018) | Hematological, N = 91 at baseline, 67% male, mean age 49 (SD 8), N = 52 at T1, N = 40 at T2, 10% self-employed, Germany | Longitudinal, baseline (less than 4 weeks before treatment), 6 months, and 1 year | WAI | Mean WAI significantly increased from 18.5 at baseline to 28.3 after 12 months (p = 0.001) | ||||
Ho et al. (2018) | Breast, N = 327, female, 6% recurrent disease, mean age at time of diagnosis: 47 (range 42–52), mean age at time of survey: 53 (range 48–58), 53% employed, Singapore | Cross-sectional, 3–8 years after diagnosis | WAI | Item 1 N = 168 employed: work ability 8% poor, 29% moderate, 48% good, and 15% excellent | Survivors with suboptimal work ability expressed more breast and arm symptoms, as compared with survivors with good or excellent work ability | General, physical, and mental fatigue were less common in survivors with optimal work ability Higher level of physical fatigue remained significant-ly associated with poorer work ability in the full model | Breast cancer survivors with suboptimal current workability had lower scores for cognitive functioning | |
Kiserud et al. (2016) | Lymphoma. N = 312, also second cancers, 85% working or on sick leave at baseline and 58% at moment of survey, 40% female, mean age 41.5 (SD 13.5) at diagnosis and 54.0 (SD 11.3) at time of survey, Norway | Cross-sectional follow-up study, mean time from diagnosis to survey was 12.4 years (SD 6.1) and from HDT-ASCT to survey 9.7 years (SD 5.1) | WAI items 1 and 2 | Item 1: The subgroup employed at follow up: 9.2 (SD 1.8) at diagnosis and 7.3 (SD 2.5) at moment of survey | ||||
Lee et al. (2008) | Stomach, N = 408, 73.5% male, also self-employed and not-working included, also 994 general population, Korea | Case control, 21–36 months after diagnosis | Multiple-choice item regarding lessened work-related ability than before cancer diagnosis | More cancer survivors had lessened work-related ability (37%) than the general population (10.6%), OR 6.11, CI 3.64–10.27 | Easily fatigued and exhausted in the workplace: 50% of the cancer survivors versus 22.4% in the general population (OR 4.02, CI 2.55–6.33) No data on the association with work ability | |||
Lindbohm et al. (2012) | Breast, testicular, prostate, or lymphoma, N = 1449, 66% female, age 25–57 at time of diagnosis, reference group N = 2709, Denmark, Finland, Iceland, and Norway (in the Iceland sample cancer recurrence excluded) | Case control, 1–8 years after diagnosis | WAI item 1 | Item 1: age-adjusted mean work ability was slightly lower among the breast cancer survivors (8.41) than among the female reference group (8.58, p < .01). No difference in work ability between men with testicular cancer diagnosis (8.76) and the male reference group (8.69). Prostate cancer survivors had a lower work ability (8.28) than the male reference group (p < .01) | Low support from supervisor or colleagues were associated with low work ability among both men and women, in the cancer group and the reference group High colleagues’ avoidance behavior was related to lower work ability among female cancer survivors (p < .001) (and not in female references) Supervisors’ high avoidance behavior was related to lower work ability among male cancer survivors (p < .01) (and not in references) No data of an association of social climate with work ability | |||
Moskowitz et al. (2014) | Breast, testicular, colorectal, and prostate cancer, Hodgkin lymphoma and non-Hodgkin Lymphoma, among others, N = 1525, 15.8% recurrence or secondary cancer, 61.6% female, mean age 49.1 (SD 10.8), also self-employed included, United States of America | Cross-sectional, average time since completion of treatment was 3 years (range 0–464 months) | Whether unable to work full time, unable to work the same as before cancer, or unable to work at all | A greater level of functional limitations (physical, cognitive and social) were significantly related to limited work ability (β = 5.88, p < .001) | A greater level of functional limitations (physical, cognitive and social) were significantly related to limited work ability (β = 5.88, p < .001) A greater level of symptoms (cognitive, distress, fatigue, cancer fear, family fear) were not significantly related to limited work ability | A greater level of symptoms (cognitive, distress, fatigue, cancer fear, family fear) were not significantly related to limited work ability | ||
Musti et al. (2018) | Breast, N = 503, mean age 51.5 (SD 3.6), permanent, fixed term and other type of contract, Italy | Cross-sectional, survey 3.2 (SD 0.9) years since treatment, retrospective about moment return to work (23.0% experienced > 6 months sick leave) | Same or reduced work ability | 43.5% reduced work ability at moment of return to work | Support/solidarity from employer 85.1% in group with no reduced work ability and 70.2% in group with reduced work ability, p < 0.001 Support/solidarity from colleagues 91.5% in group with no reduced work ability and 76.8% in group with reduced work ability, p < 0.001 | |||
Neudeck et al. (2017) | Thyroid, N = 66, 69.7% female, 68% working, Switzerland | Cross-sectional, max. 7 years after treatment. Mean time since the diagnosis of thyroid cancer was 37.8 months (SD: 21.7; range: 7–79) | Ad hoc question-naire | 71.2% felt impaired with respect to their work ability during the first year after the diagnosis | ||||
Nieuwenhuijsen et al. (2009) | Gastrointestinal, breast, female genitals, male genitals, urological haematological, and other types, primary diagnosis of cancer, N = 195 at T1 (of whom N = 45 neuropsychological tested at T2), 67% female, mean age 44 (SD 9), the Netherlands | Longitudinal (prospective), T1 = 6 months after first day of sick leave, T2 = 12 months after first day of sick leave, also neuro-psychological testing, T3 = 18 months after first day of sick leave | WAI item 1 on T2 | Item 1: At T1 no difference (p = .27) between the participants in the neuro- psychological study (4.1, SD 3.0) and the rest of the cohort (4.7, SD 3.3) | ||||
Nilsson et al. (2016) | Breast, female, N = 692 at T1, mean age 50.8 (SD 8.07), Sweden | Longitudinal (prospective), T1 = 4 weeks after surgery T2–T6 during 24 months | WAI item 2 | Item 2: significant difference in physical work ability between baseline (β = 0.354, p < .001) and 4 months (β = 0.138, p < .001) as well as between 4 and 8 months (β = 0.285, p < .001) Item 2: significant differences in mental/social work ability were found between 8 and 12 months (β = 0.286, p < .001) | ||||
Ortega et al. (2018) | Breast, N = 114 (three treatment groups of N = 38), female, mean ages 48.1–50.1, self-employed 36.8–52.6%, Brazil | Cross-sectional, > 1 year after treatment | Work Limitations Questionnaire (the percentage of time limited in performing work tasks in the last 2 weeks) | Patients in the mastectomy and breast-conserving surgery groups showed reduced work effectiveness (presenteeism) and loss of productivity compared with women in the breast reconstruction and control groups (p = 0.0004 and p = 0.0006, respectively) | ||||
Tamminga et al. (2019) | Breast (61%), gynecological cancer (35%), or other type of cancer (4%) Intervention group N = 49, mean age 47.1 (SD 8.2), 98% female Control group N = 57, mean age 47.8 (SD 7.6), 100% female, 4% self-employed, The Netherlands | Longitudinal, baseline and at 6, 12, 18, and 24 months of follow-up | WAI items 1 and 2 | Work ability improved from baseline to 1 year and stable from 1 to 2 years | ||||
Taskila et al. (2007) | Breast, lymphoma, testicular or prostate, no distant metastasis, N = 591, 73,9% female, age 25–57 at time of diagnosis, also freelancers and entrepreneurs included, also 757 referents, Finland | Case control, 2–6 years after diagnosis | WAI items 1 and 2 | Item 1: nearly the same as in referents and highest mean value for men with testicular cancer (8.95), and lowest for men with prostate cancer (8.00) Item 2: 26% reported deteriorated physical work ability due to cancer 19% reported deteriorated mental work ability due to cancer | Among the female survivors (and male referents, but not among male survivors), co-workers’ support was related to reduced risk of impaired physical work ability (OR 0.83, CI 0.73–0.94) and for impaired mental work ability (OR 0.84, CI 0.73–0.96) A better social climate at work was only related to impaired mental work ability (and not to physical work ability), for male survivors (OR 0.80, CI 0.70–0.91) and for female survivors (OR 0.84, CI 0.76–0.94) | |||
Torp et al. (2012) | 15 most common cancers: like breast, gynecological, prostate, testicular, N = 653, primary diagnoses, 9% with metastasis, 68% female, mean age 51.9 (SD 7.9), 6% self-employed, Norway | Cross-sectional, 15–39 months after cancer diagnosis | WAI items 1 and 2 | Item 1: mean total (current) work ability was 8.6 (SD 1.8) among men and 8.6 (SD 1.7) among women Self-employment was a predictor for lower work ability. Comorbidity (36%) was strongly correlated with work ability Item 2: 31% reported a reduction in physical work ability due to cancer 23% reported a reduction in mental work ability. More women than men had reduced mental work ability due to cancer | General social support (β = 0.15, p ≤ .001) is a significant predictor of total work ability in univariate (and not in multivariate) regression Cancer-related colleague support was a significant predictor of total work ability (β = 0.15, p ≤ .01) in multivariate regression Cancer-related supervisor support was not a significant predictor of total work ability in regression analyses Decision latitude (β = 0.08, p ≤ .05) is a significant predictor of work ability in univariate (and not in multivariate) regression | |||
Torp et al. (2017) | Most common invasive types of cancer: colon, rectal, lung, skin (melanoma), breast, cervical, uterine, ovarian, prostate, testicular, bladder, central nervous system, thyroid, non-Hodgkin lymphoma, and leukemia, N = 1115, 69% female, 8% self-employed Not returned to work at time of survey: 24% self-employed and 18% salaried | Cross-sectional, 15–39 months after diagnosis | WAI items 1 and 2 | Item1: compared with the salaried workers, the self-employed people reported significantly more often reduced total work ability (p = .02, effect size 0.26). The negative effect of self-employment on total work ability seems to be mediated by reduced work hours and a negative cancer-related financial change Item 2: no significant differences between the salaried and the self-employed | Poor-self rated health status correlated significantly with low total work ability in logistic regression analyses | Having higher decision latitude at work was a factor preventing low total work ability (OR 0.80, CI 0.68–0.94) | ||
Von Ah et al. (2018) | Breast, N = 68, exclusion of secondary cancers or metastasis, mean age 52.12 (SD 8.16), United States of America | Cross-sectional, study population on average 5 (SD 3.8) years post-treatment (minimum 1 year) | WAI | Mean 38.9 (SD 7.5). Poor or moderate work ability: 26.5% | Significant relationship between perceived cognitive impairment and work ability (β = − 0.658, p < .000) Explained variance: 46,5% Significant relationship between perceived cognitive ability and work ability (β = 0.472, p < .000) Explained variance: 29,9% | |||
Von Ah et al. (2017) | Breast N = 68, exclusion of brain metastasis, mean age 52.12 (SD 8.603), 1% self-employed, United States of America | Cross-sectional, study population on average 4.97 (SD 3.36) years post-treatment (minimum 1 year) | WAI | WAI: Mean 38.91 (SD 7.45) Poor 7–27: 10%, moderate 28–36: 16%, good 37–43: 46%, excellent 44–49: 28% | Linear regression: significant relationship between attentional fatigue (higher = higher level of attention) and perceived work ability (ß = 0.627, p < .001), Explained variance: 39% | |||
Wolvers et al. (2019) | Breast 84%, colorectal, Non-Hodgkin, lymphoma, other, N = 89, 91% female, mean age 47.9 (7.2), 10% self-employed, The Netherlands | Longitudinal intervention study, baseline, 6, 12, 18 months | WAI item 1 | Inverse, longitudinal association between fatigue and perceived work ability | ||||
Zanville et al. (2016) | Breast, N = 44 (22 chemo-therapy-treated and 22 chemo-therapy-naïve), non-metastatic, female, mean age resp. 49.68 (SD 8.0) and 52.68 (SD 9.3), United States of America | Longitudinal, T0 = pre-treatment (approximately one third of chemotherapy-treated received neo-adjuvant chemotherapy and were surgery and treatment naïve at baseline), T1 = approximately 1-month post-chemotherapy, T2 = approximately 1 year after T1 | Item from Functional Well-Being subscale of FACT/GOG-Ntx (version 4) | – |
Quality assessment
Bains et al. (2012) | De Boer et al. (2008) | Couwenberg et al. (2020) | Doll et al. (2016) | Duijts et al. (2017) | Gregorowitsch et al. (2019) | Hartung et al. (2018) | Nieuwenhuijsen et al. (2009) | Nilsson et al. (2016) | Tamminga et al. (2019) | Wolvers et al. (2019) | Zanville et al. (2016) | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1. Did the study address a clearly focused issue? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
2. Was the cohort recruited in an acceptable way? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
3. Was the exposure accurately measured to minimize bias? | Yes | Yes | Yes | No Benign tumors included | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
4. Was work ability accurately measured to minimize bias? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
5. Have the authors identified all important confounding factors? | Yes | N.a | Yes | N.a | N.a | N.a | Yes | N.a | N.a | Yes | Yes | Yes |
6. Have they taken account of the confounding factors in the design and/or analysis? | Yes | N.a | Yes | N.a | N.a | N.a | Yes | N.a | N.a | Yes | Yes | Yes |
7. Was the follow up of subjects complete enough? | Yes | Yes | Yes | N.a. | N.a | Yes | Yes | N.a | N.a | Yes | Yes | Yes |
8. Was the follow up of subjects long enough to investigate late effects? | No (6 months) | No (18 months) | No (24 months) | No (6 months) | Yes | Yes | No (12 months) | No (18 months) Sub study was cross-sectional | No (2 years) | No (2 years) | No (18 months) | No (1 year) |
9. What are the results of this study? | See Table 1 | See Table 1 | See Table 1 | See Table 1 | See Table 1 | See Table 1 | See Table 1 | See Table 1 | See Table 1 | See Table 1 | See Table 1 | See Table 1 |
10. Are the results precise? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
11 Do you believe the results? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
12. Can the results be applied to the local (European) population? | Yes | Yes | Yes | No (USA) | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No (USA) |
13. Do the results of this study fit with other available evidence with regard to work ability? | Yes | Yes | Yes | N.a | N.a | Yes | Yes | N.a | N.a | Yes | Yes | Yes |
14. What are the implications of this study for practice? | See Table 1 | See Table 1 | See Table 1 | See Table 1 | See Table 1 | See Table 1 | See Table 1 | See Table 1 | See Table 1 | See Table 1 | See Table 1 | See Table 1 |
Carlsen et al. (2013) | Gudbergsson et al. (2008a) | Gudbergsson et al. (2011) | Lee et al. (2008) | Lindbohm et al. (2012) | Taskila et al. (2007) | |
---|---|---|---|---|---|---|
1. Did the study address a clearly focused issue? | Yes | Yes | Yes | Yes | Yes | Yes |
2. Did the authors us an appropriate method to answer their question? | Yes | Yes | Yes | Yes | Yes | Yes |
3. Were the cases recruited in an acceptable way? | Yes | Yes | Yes | Yes | Yes | Yes |
4. Were the controls selected in an acceptable way? | Yes | Yes | Yes | Yes | Yes | Yes |
5. Was the exposure accurately measured to minimize bias? | Yes | Yes | Yes | Yes | Yes | Yes |
6. Aside from the experimental intervention (cancer–no cancer), were the groups treated equally? | Yes | Yes | Yes | Yes | Yes | Yes |
7. Have the authors taken account of the potential confounding factors in the design and/or in their analysis? | Yes | Yes | Yes | Yes | Yes | Yes |
8. How large was the treatment (cancer–no cancer) effect? | See Table 1 | See Table 1 | See Table 1 | See Table 1 | See Table 1 | See Table 1 |
9. How precise was the estimate of the treatment effect? | N.a | N.a | N.a | N.a | N.a | N.a |
10. Do you believe the results? | Yes | Yes | Yes | Yes | Yes | Yes |
11. Can the results be applied to the local (European) population? | Yes | Yes | Yes | No (Korea) | Yes | Yes |
12. Do the results of this study fit with other available evidence? | Yes | Yes | Yes | Yes | Yes | Yes |
Bielik et al. (2020) | Cheung et al. (2017) | Dahl et al. (2020) | Dahl et al. (2016) | Dahl et al. (2019) | De Boer et al. (2011) | Fosså et al. (2015) | Gudbergsson et al. (2008b) | Ho et al. (2018) | Kiserud et al. (2016) | Moskowitz et al. (2014) | Musti et al. (2018) | Neudeck et al. (2017) | Ortega et al. (2018) | Torp et al. (2012) | Torp, Syse et al. (2017) | Von Ah et al. (2018) | Von Ah et al. (2017) | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1. Were the aims/objectives of the study clear? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
2. Was the study design appropriate for the stated aim(s)? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
3. Was the sample size justified? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
4. Was the target/reference population clearly defined? Is it clear who the research was about? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
5. Was the sample frame taken from an appropriate population base so that it closely represented the target/reference population under investigation? | Yes | Don’t know. Convenience sample from three sources | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
6. Was the selection process likely to select subjects/participants that were representative of the target/reference population under investigation? | Don’t know. Partly pilot study | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Don’t know. Pilot study | Yes | Yes | Yes | Yes | Yes |
7. Were measures undertaken to address and categorize non-responders? | Don’t know. No information | Yes | Yes | Don’t know Data from other studies | N.a | Yes | No | Yes | Yes | Yes | No | Yes | No | Don’t know. No information | No | No | No | No |
8. Was work ability measured appropriate to the aims of the study? | Mixed: current work ability appropriate, work ability unclear | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
9. Was work ability measured correctly using instruments/measurements that had been trailed, piloted or published previously? | Don’t know | Yes | Yes | Yes | Yes | Yes | Don’t know. No information | Yes | Yes | Yes | Don’t know. No information | Don’t know. No information | No A non-validated ad hoc questionnaire | Yes | Yes | Yes | Yes | Yes |
10. Is it clear what was used to determined statistical significance and/or precision estimates? (e.g., p values, CIs) | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
11. Were the methods (including statistical methods) sufficiently described to enable them to be repeated? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
12. Were the basic data adequately described? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Time since diagnosis unclear | Yes | Yes | Yes | Yes |
13. Does the response rate raise concerns about non-response bias? | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No |
14. If appropriate, was information about non-responders described? | Yes | Yes | Yes | No | N.a | Yes | No | Yes | Yes | Yes | No | Yes | No | Yes | No | No | No | No |
15. Were the results internally consistent? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
16. Were the results for the analyses described in the methods, presented? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
17. Were the authors’ discussions and conclusions justified by the results? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
18. Were the limitations of the study discussed? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
19. Were there any funding sources or conflicts of interest that may affect the authors’ interpretation of the results? | No | No | No | No | No | No | No | No | No | No | No | No | Don’t know. Pilot study | No | No | No | No | No |
20. Was ethical approval or consent of participants attained? | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |